These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34999929)

  • 61. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
    Abdel-Azim H; Mahadeo KM; Zhao Q; Khazal S; Kohn DB; Crooks GM; Shah AJ; Kapoor N
    Am J Hematol; 2015 Nov; 90(11):1021-6. PubMed ID: 26242764
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
    Leuk Lymphoma; 2018 Apr; 59(4):837-843. PubMed ID: 28782395
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India.
    Swaminathan VV; Uppuluri R; Patel S; Ravichandran N; Ramanan KM; Vaidhyanathan L; Ramakrishnan B; Jayakumar I; Raj R
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High dose total marrow irradiation (TMI) does not increase long-term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT).
    Maahs L; Patel P; Koshy M; Sweiss K; Chen Z; Xu Z; Aydogan B; Rondelli D
    Eur J Haematol; 2024 Jul; 113(1):110-116. PubMed ID: 38566462
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
    Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
    J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
    Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
    Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
    Nemecek ER; Guthrie KA; Sorror ML; Wood BL; Doney KC; Hilger RA; Scott BL; Kovacsovics TJ; Maziarz RT; Woolfrey AE; Bedalov A; Sanders JE; Pagel JM; Sickle EJ; Witherspoon R; Flowers ME; Appelbaum FR; Deeg HJ
    Biol Blood Marrow Transplant; 2011 Mar; 17(3):341-50. PubMed ID: 20685259
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
    Slatter MA; Rao K; Amrolia P; Flood T; Abinun M; Hambleton S; Nademi Z; Goulden N; Davies G; Qasim W; Gaspar HB; Cant A; Gennery AR; Veys P
    Blood; 2011 Apr; 117(16):4367-75. PubMed ID: 21325599
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia.
    Lee SS; Jung SH; Do YR; Kim DS; Lee JH; Park HS; Moon JH; Yi JH; Park Y; Koh Y; Yhim HY; Choi Y; Mun YC; Lee WS; Lee S; Yang DH;
    Yonsei Med J; 2020 Jun; 61(6):452-459. PubMed ID: 32469169
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
    Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.
    Kanakry CG; O'Donnell PV; Furlong T; de Lima MJ; Wei W; Medeot M; Mielcarek M; Champlin RE; Jones RJ; Thall PF; Andersson BS; Luznik L
    J Clin Oncol; 2014 Nov; 32(31):3497-505. PubMed ID: 25267759
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy.
    Messina C; Zecca M; Fagioli F; Rovelli A; Giardino S; Merli P; Porta F; Aricò M; Sieni E; Basso G; Ripaldi M; Favre C; Pillon M; Marzollo A; Rabusin M; Cesaro S; Algeri M; Caniglia M; Di Bartolomeo P; Ziino O; Saglio F; Prete A; Locatelli F
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1223-1231. PubMed ID: 29410181
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases.
    Nishimura A; Aoki Y; Ishiwata Y; Ichimura T; Ueyama J; Kawahara Y; Tomoda T; Inoue M; Matsumoto K; Inoue K; Hiroki H; Ono S; Yamashita M; Okano T; Tanaka-Kubota M; Ashiarai M; Miyamoto S; Miyawaki R; Yamagishi C; Tezuka M; Okawa T; Hoshino A; Endo A; Yasuhara M; Kamiya T; Mitsuiki N; Ono T; Isoda T; Yanagimachi M; Tomizawa D; Nagasawa M; Mizutani S; Kajiwara M; Takagi M; Kanegane H; Imai K; Morio T
    J Clin Immunol; 2021 Jul; 41(5):944-957. PubMed ID: 33527309
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treosulfan-based reduced toxicity hematopoietic stem cell transplantation in X-linked agammaglobulinemia: A cost-effective alternative to long-term immunoglobulin replacement in developing countries.
    Vellaichamy Swaminathan V; Uppuluri R; Patel S; Melarcode Ramanan K; Ravichandran N; Jayakumar I; Vaidhyanathan L; Raj R
    Pediatr Transplant; 2020 Feb; 24(1):e13625. PubMed ID: 31821668
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Successful Myeloablative Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in a Young Girl With GATA2 Deficiency and Emberger Syndrome.
    Ramzan M; Lowry J; Courtney S; Krueger J; Schechter Finkelstein T; Ali M
    J Pediatr Hematol Oncol; 2017 Apr; 39(3):230-232. PubMed ID: 28234738
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
    Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
    Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.